Company Overview and News

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.
Upvote Downvote

 
Shares fall as investors weight up Fletcher rights issue

2018-04-17 nzherald.co.nz
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.
Upvote Downvote

 
NZ shares fall as Pushpay revenue slips

2018-04-11 nzherald.co.nz
New Zealand shares fell, led by Pushpay Holdings after the mobile app payments developer posted its first dip in quarterly revenue, while blue-chip stocks a2 Milk Co, Fletcher Building and Fisher & Paykel Healthcare declined. Infratil gained on upbeat earnings guidance.
Upvote Downvote

 
Fletcher price slide sparks fears of index and investor exit

2018-04-08 nzherald.co.nz
Fletcher Building is trading at its lowest price in nearly a decade, sparking fears it could soon drop out of a key sharemarket index, which may well see big-time investors dump the stock.
Upvote Downvote

 
NZ shares drop; Fletcher closes at 9-year low

2018-04-05 nzherald.co.nz
New Zealand shares fell, led by Sky Network Television, Genesis Energy and Fletcher Building while Kathmandu Holdings and Synlait Milk gained.
Upvote Downvote

 
Australian shares steady, Santos soars to intraday record on new bid, NZ edges up

2018-04-03 reuters
April 3 (Reuters) - Australian shares began the quarter on a steady note as losses in financial stocks slightly outweighed gains in materials stocks and energy major Santos, which soared on a sweetened takeover offer.
Upvote Downvote

 
Global appetite for NZ yield stocks on pause, Harbour Asset's Bascand says

2018-03-25 nbr.co.nz
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.
Upvote Downvote

 
MARKET CLOSE: NZ shares drop 1% on global selloff, US stocks wobble as Trump backs down on spending bill

2018-03-23 nbr.co.nz
New Zealand's NZX 50 Index dropped nearly 1 percent on global trade news in Friday trading., with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
Upvote Downvote

1
Global appetite for NZ yield stocks on'pause, Harbour Asset's Bascand says

2018-03-23 nbr.co.nz
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.
Upvote Downvote

 
Shares drop 1% on global selloff, led by Synlait, Sky TV

2018-03-23 nzherald.co.nz
New Zealand's NZX 50 Index dropped nearly 1 per cent on global trade news, with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
Upvote Downvote

 
Auckland Airport reports 92% surge in Chinese arrivals in February

2018-03-22 nzherald.co.nz
Auckland International Airport reported a 92 per cent surge in Chinese arrivals in February, due to the timing of Chinese New Year, but New Zealand's biggest gateway is also benefitting from a consistent lift in visitors from China as part of a broader boom in tourism.
Upvote Downvote

 
MARKET CLOSE: NZ shares rise on Summerset upgrade; Synlait gains while Argosy, Strike shed dividends

2018-03-13 nbr.co.nz
New Zealand shares rose, bucking a selloff in most stock markets across Asia, as an analyst upgrade for Summerset Group pushed the retirement village operator to a record high. Synlait Milk gained, while Stride Property and Argosy Property fell after shedding dividend rights.
Upvote Downvote

 
MARKET CLOSE: NZ shares join global rally as trade fears ease; Chorus, Mainfreight rise

2018-03-06 nbr.co.nz
New Zealand shares rose as fears eased over US President Donald Trump's new tariffs on metals, renewing demand for equities across the world. Chorus and Mainfreight gained, while Metro Performance Glass fell, matching its record low.
Upvote Downvote

 
NZ shares join global rally as trade fears ease

2018-03-06 nzherald.co.nz
New Zealand shares rose as fears eased over US President Donald Trump's new tariffs on metals, renewing demand for equities across the world. Chorus and Mainfreight gained, while Metro Performance Glass fell, matching its record low.
Upvote Downvote

 
NZ shares follow Asian markets lower

2018-03-01 nzherald.co.nz
New Zealand shares joined a regionwide sell-off with Asian equity markets following Wall Street lower as global investors second-guess the outlook for US interest rates, and as local analysts absorb a "pretty good" earnings season. Sky Network Television fell for a second day.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...